TI
ELVN icon

Trexquant Investment’s Enliven Therapeutics ELVN Stock Holding History

Trexquant Investment’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.9M Sell
37,491
-40,757
-52% -$1.73M 0.01% 1216
2026
Q1 		$3.07M Buy
+78,248
New +$2.17M 0.02% 838
2025
Q4 		– Sell
-50,492
Closed -$1.03M – 1663
2025
Q3 		$1.03M Buy
50,492
+24,965
+98% +$503K 0.01% 1141
2025
Q2 		$512K Buy
+25,527
New +$483K 0.01% 1260
2021
Q4 		– Sell
-4,912
Closed -$80K – 1380
2021
Q3 		$80K Buy
+4,912
New +$102K 0.01% 1067

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Trexquant Investment's ELVN Position: Q2 2026 in Review

Trexquant Investment reduced its Enliven Therapeutics (ELVN) stake by 52% in Q2 2026, selling an estimated $1.73M and leaving 37,491 shares worth $1.9M. The position accounts for 0.01% of the portfolio, ranked #1216.

Trexquant Investment first reported a position in ELVN in Q3 2021 and has held it in 5 quarters since. The position peaked at $3.07M in Q1 2026. 213 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • Trexquant Investment held 37,491 shares of Enliven Therapeutics worth $1.9M as of Q2 2026.
  • Trexquant Investment sold 40,757 Enliven Therapeutics shares in Q2 2026, an estimated $1.73M.
  • Enliven Therapeutics made up 0.01% of Trexquant Investment's portfolio in Q2 2026, its #1216 holding.
  • Trexquant Investment first reported a position in Enliven Therapeutics in Q3 2021 and has held it in 5 quarters since.
  • Trexquant Investment's Enliven Therapeutics position peaked at $3.07M in Q1 2026.
  • 213 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on Trexquant Investment's 13F filing for Q2 2026, filed 14 Aug 2026.